PD-L1 expression as a predictive biomarker in cancer immunotherapy

Cited by (1,001)

Items 401–500 of 1,001

1. Biomimetic Nanovehicle-Enabled Targeted Depletion of Intratumoral Fusobacterium nucleatum Synergizes with PD-L1 Blockade against Breast Cancer
   Shizhen Geng, Pengke Guo, Xinling Li, Yaru Shi, Jing Wang, Mengnian Cao, Yunya Zhang, Kaixiang Zhang, Airong Li, Haiwei Song et al. · 2024 · ACS Nano
2. Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome
   Shuhei Ito, Shinji Okano, Masaru Morita, Hiroshi Saeki, Satoshi Tsutsumi, Hiroshi Tsukihara, Yuichiro Nakashima, Koji Ando, Yu Imamura, Kippei Ohgaki et al. · 2016 · Annals of Surgical Oncology
3. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors
   Wei Wei, Bin Xu, Yan Wang, Chen Wu, Jingting Jiang, Changping Wu · 2018 · Medicine
4. Conjunctival Melanoma: Current Treatments and Future Options
   Joseph M. Grimes, Nirav V. Shah, Faramarz H. Samie, Richard D. Carvajal, Brian P. Marr · 2020 · American Journal of Clinical Dermatology
5. Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer
   Takahide Toyoda, Toshiko Kamata, Kazuhisa Tanaka, Fumie Ihara, Mariko Takami, Hidemi Suzuki, Takahiro Nakajima, Takayuki Ikeuchi, Yohei Kawasaki, Hideki Hanaoka et al. · 2020 · Journal for ImmunoTherapy of Cancer
6. Cuprotosis Programmed-Cell-Death-Related lncRNA Signature Predicts Prognosis and Immune Landscape in PAAD Patients
   Hao Chi, Gaoge Peng, Rui Wang, Fengyi Yang, Xixi Xie, Jinhao Zhang, Ke Xu, Tao Gu, Xiaoli Yang, Gang Tian · 2022 · Cells
7. Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review
   Alejandro Olivares-Hernández, Elisabet González-Del Portillo, Álvaro Tamayo-Velasco, Luis Figuero-Pérez, Svetlana Zhilina-Zhilina, Emilio Fonseca‐Sánchez, José Pablo Miramontes‐González · 2023 · Annals of Translational Medicine
8. OX40/OX40 ligand and its role in precision immune oncology
   Bicky Thapa, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline, Rebecca A. Previs, Jeff Conroy, Paul DePietro, Sarabjot Pabla et al. · 2024 · Cancer and Metastasis Reviews
9. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
   Shumei Kato, Ryosuke Okamura, Yuichi Kumaki, Sadakatsu Ikeda, Mina Nikanjam, Ramez Nassef Eskander, Aaron Michael Goodman, Suzanna Lee, Sean T. Glenn, Devin C. Dressman et al. · 2020 · OncoImmunology
10. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
    Helen Kotanides, Yiwen Helen Li, Maria Malabunga, Carmine Carpenito, Scott W. Eastman, Yang Shen, George Wang, Ivan V. Inigo, David Surguladze, Anthony L. Pennello et al. · 2020 · Cancer Immunology Research
11. Immuno-oncology trends: preclinical models, biomarkers, and clinical development
    Maryland Rosenfeld Franklin, Suso J. Platero, Kamal S. Saini, Giuseppe Curigliano, Steven Anderson · 2022 · Journal for ImmunoTherapy of Cancer
12. Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions
    Kartik Mandal, Ganesh Kumar Barik, Manas Kumar Santra · 2025 · Molecular Cancer
13. Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer
    Kostandinos Sideras, Katharina Biermann, Kevin Yap, Shanta Mancham, Patrick P.C. Boor, Bettina E. Hansen, Hans Stoop, Maikel Petrus Peppelenbosch, Casper H.J. van Eijck, Stefan Sleijfer et al. · 2017 · International Journal of Cancer
14. Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
    Kazuo Okadome, Yoshifumi Baba, Daichi Nomoto, Taisuke Yagi, Rebecca Kalikawe, Kazuto Harada, Yukiharu Hiyoshi, Yohei Nagai, Takatsugu Ishimoto, Masaaki Iwatsuki et al. · 2020 · British Journal of Cancer
15. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+triple negative breast cancer cells
    Nishant Mohan, Salman B. Hosain, Jun Wei Zhao, Yi Shen, Xiao Ling Luo, Jiangsong Jiang, Yukinori Endo, Wen Jin Wu · 2019 · OncoImmunology
16. Variant Hepatocellular Carcinoma Subtypes According to the 2019 WHO Classification: An Imaging-Focused Review
    Liang Meng Loy, Hsien Min Low, Jin-Young Choi, Hyungjin Rhee, Chin Fong Wong, Cher Heng Tan · 2022 · American Journal of Roentgenology
17. Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients
    Masato Kobayashi, Jin‐Sung Chung, Muhammad Shaalan Beg, Yull Edwin Arriaga, Udit N. Verma, Kevin Dale Courtney, John C. Mansour, Barbara Haley, Saad A. Khan, Yutaka Horiuchi et al. · 2018 · Clinical Cancer Research
18. Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
    Andreas N. WICKI, Mario Mandalà, Daniela Massi, Daniela Taverna, Huifang Tang, Brian A. Hemmings, Gongda Xue · 2016 · Physiological Reviews
19. Selective reactivation of STING signaling to target Merkel cell carcinoma
    Wei Liu, Gloria B. Kim, Nathan A. Krump, Yuqi Zhou, James L. Riley, Jianxin You · 2020 · Proceedings of the National Academy of Sciences
20. A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
    Yu Fujiwara, Arjun Mittra, Abdul Rafeh Naqash, Naoko Takebe · 2020 · Cancer Drug Resistance
21. Supramolecular Immunotherapy of Cancer Based on the Self‐Assembling Peptide Design
    Rui Chang, Xuehai Yan · 2020 · Small Structures
22. DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
    Katharina Filipski, Michael Scherer, Kim Nikola Zeiner, Andreas Michael Bucher, Johannes Kleemann, Philipp Sebastian Jurmeister, Tabea Isabelle Hartung, Markus Meißner, Karl Heinz Plate, Tim R. Fenton et al. · 2021 · Journal for ImmunoTherapy of Cancer
23. Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine
    Nicolas D. Huyghe, Elena Benidovskaya, Philippe Stevens, Marc Van den Eynde · 2022 · Cancers
24. Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy
    T. M. Mohiuddin, Chaoyu Zhang, Wenjie Sheng, Marwah Al-Rawe, Felix Alexander Zeppernick, Ivo M. Meinhold-Heerlein, Ahmad Fawzi Hussain · 2023 · International Journal of Molecular Sciences
25. Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
    Saud Almawash · 2025 · Cancers
26. Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in 18F-FDG PET in Squamous Cell Carcinoma of the Head and Neck
    Rui-Yun Chen, Ying‐Chun Lin, Wei-Chih Shen, Te‐Chun Hsieh, Kuo‐Yang Yen, Shang-Wen Chen, Chia‐Hung Kao · 2018 · Scientific Reports
27. PD-L1 expression in medulloblastoma: an evaluation by subgroup
    Allison M. Martin, Christopher J. Nirschl, Magdalena J. Polanczyk, W Robert Bell, Thomas R. Nirschl, Sarah Harris‐Bookman, Jillian A. Phallen, Jessica L Hicks, Daniel Martínez, Aleksandra Ogurtsova et al. · 2018 · Oncotarget
28. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma
    Shengchao Xu, Lu Tang, Zhixiong Liu, Chengke Luo, Quan Cheng · 2021 · Frontiers in Immunology
29. Tumour Necrosis Factor Alpha (TNF-α) and Oral Squamous Cell Carcinoma
    Gary Ian Brierly, Antonio Celentano, Omar Breik, Elham Moslemivayeghan, Romeo Patini, Michael John McCullough, Tami Yap · 2023 · Cancers
30. Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low
    Xie Hu, Ping Yang, Songhao Chen, Gang Wei, Lijuan Yuan, Zhenyu Yang, Li Gong, Li He, Lin Yang, Shujia Peng et al. · 2023 · Breast Cancer Research
31. Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring
    Chunyan Liu, Fang Fang, Ying Kong, Ehab A. ElGabry · 2023 · Diagnostic Pathology
32. Alginate-Chitosan Biodegradable and Biocompatible Based Hydrogel for Breast Cancer Immunotherapy and Diagnosis: A Comprehensive Review
    Pratikshya Patra, Tarun Kumar Upadhyay, Nawaf I. Alshammari, Mοhd Saeed, Kavindra Kumar Kesari · 2024 · ACS Applied Bio Materials
33. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model
    Weiwei Wang, Ling Wu, Jiansheng Zhang, Huiguo Wu, En-Kun Han, Qiang Guo · 2016 · Biochemical and Biophysical Research Communications
34. A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/AkT/MTOR signaling pathway
    Lei Zhao, Cheng Li, Fei Liu, Yonghong Zhao, Jun Liu, Ye Hua, Jinyang Liu, Jiapeng Huang, Chunlin Ge · 2017 · OncoTargets and Therapy
35. Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology
    Cesare Gridelli, Andrea Ardizzoni, Massimo C.P. Barberis, Federico Cappuzzo, Francesca Casaluce, Romano Danesi, Giancarlo Troncone, Filippo de Marinis · 2017 · Translational Lung Cancer Research
36. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients
    Johannes Breyer, Ralph Markus Wirtz, Wolfgang Otto, Philipp Erben, Thomas Stefan Worst, Robert Stoehr, Markus Eckstein, Stefan Denzinger, Maximilian Burger, Arndt Hartmann · 2017 · Cancer Immunology Immunotherapy
37. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification
    Stefan Gröschel, Martin Bommer, Barbara Hutter, Jan Budczies, David Bonekamp, Christoph Heining, Peter Horak, Martina Fröhlich, Sebastian Uhrig, Daniel Hübschmann et al. · 2016 · Molecular Case Studies
38. The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma
    Ling Wang, Fubiao Kang, Nan Sun, Juan Wang, Wei Chen, Dong Li, Baoen Shan · 2016 · Tumor Biology
39. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes
    Suzanne M. Crumley, Katherine C. Kurnit, Courtney W. Hudgens, Bryan M. Fellman, Michael T. Tetzlaff, Russell R. Broaddus · 2018 · Modern Pathology
40. A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
    Mohammad Jafarnejad, Chang Gong, Edward Gabrielson, Imke Heleen Bartelink, Paolo Vicini, Bing Wang, Rajesh Narwal, Lorin K. Roskos, Aleksander S. Popel · 2019 · The AAPS Journal
41. Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities
    Julia Chang, Gefei Alex Zhu, Christine Cheung, Shufeng Li, Jinah Kim, Anne Lynn S. Chang · 2017 · JAMA Dermatology
42. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors
    Hyeyoon Chang, Jung Sun Kim, Yoon Ji Choi, Jae‐Gu Cho, Jeong‐Soo Woo, Aeree Kim, Jun Suk Kim, Eun Joo Kang · 2017 · OncoTargets and Therapy
43. Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer
    Sayuri Nakamura, Kentarō Hayashi, Yuki Imaoka, Yuka Kitamura, Yuko Akazawa, Kazuhiro Tabata, Ruben A. L. de Groen, Tomoshi Tsuchiya, Naoya Yamasaki, Takeshi Nagayasu et al. · 2017 · PLoS ONE
44. Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies
    Aaron Michael Goodman, Shumei Kato, Philip R. Cohen, Amélie Boichard, Garrett Michael Frampton, Vincent A. Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock · 2017 · OncoImmunology
45. Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma
    Erik C. Yusko, Marissa Vignali, Richard K. Wilson, Elaine R. Mardis, Frank Stephen Hodi, Christine E. Horak, Han Chang, David Michael Woods, Harlan S. Robins, Jeffrey S. Weber · 2019 · Cancer Immunology Research
46. The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
    Yanhui Chen, Yating Wang, Hongli Luo, Xue Meng, Wei Zhu, Di Wang, Hui Zeng, Henghui Zhang · 2020 · Experimental Hematology and Oncology
47. Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy
    Yang-Hong Dai, Ying-Fu Wang, Po‐Chien Shen, Cheng‐Hsiang Lo, Jen-Fu Yang, Chun‐Shu Lin, Hsing‐Lung Chao, Wen‐Yen Huang · 2021 · npj Genomic Medicine
48. Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells
    Yu‐Tang Chin, Po‐Li Wei, Yih Ho, André Wendindondé Nana, Chun A. Changou, Yi‐Ru Chen, Yu‐Chen S. H. Yang, Meng-Ti Hsieh, Aleck A. Hercbergs, Paul J. Davis et al. · 2018 · Endocrine Related Cancer
49. CCL22 Signaling in the Tumor Environment
    Natascha Röhrle, Maximilian M. L. Knott, David Anz · 2020 · Advances in experimental medicine and biology
50. An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma
    Yan‐Xing Chen, Zixian Wang, Ying Jin, Qi Zhao, Zexian Liu, Zhixiang Zuo, Huai‐Qiang Ju, Chengxu Cui, Jun Yao, Yanqiao Zhang et al. · 2023 · Cancer Cell
51. Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
    Valérie Dutoit, Denis Migliorini, Pierre‐Yves Dietrich, Paul R. Walker · 2016 · Frontiers in Oncology
52. Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia
    Shahrzad Jalali, Tammy L. Price-Troska, Jonas Paludo, Jose Caetano Villasboas, Hyo-Jin Kim, Zhi‐Zhang Yang, Anne Josephine Novak, Stephen Maxted Ansell · 2018 · Blood Advances
53. Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses
    Ying Zhu, Xiangyu Wang, Yu Zhang, Da Xu, Jian Dong, Ze Zhang, Chenhe Yi, Hu‐Liang Jia, Xin Ling Yang · 2018 · Cancer Management and Research
54. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers
    Suzanne J. Forrest, Alyaa Al‐Ibraheemi, Duong Doan, Abigail Ward, Catherine M. Clinton, Juan Putra, Robert Seth Pinches, Cigall Kadoch, Susan N Chi, Steven G. DuBois et al. · 2020 · Clinical Cancer Research
55. Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
    Timothy V. Pham, Amélie Boichard, Aaron Michael Goodman, Paul J. Riviere, Huwate Yeerna, Pablo Tamayo, Razelle Kurzrock · 2020 · Molecular Oncology
56. The Contribution of Race to Breast Tumor Microenvironment Composition and Disease Progression
    Gina Kim, Jessica M. Pastoriza, John S. Condeelis, Joseph A. Sparano, Panagiota S. Filippou, George S. Karagiannis, Maja H. Oktay · 2020 · Frontiers in Oncology
57. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
    Enliang Li, Xing Huang, Gang Zhang, Tingbo Liang · 2021 · Journal of Experimental & Clinical Cancer Research
58. Metaplastic breast cancer: A review
    Horatio R. Thomas, Bonnie Y. Hu, Bariş Boyraz, Andrew Johnson, Veerle Bossuyt, Laura M. Spring, Rachel Jimenez · 2023 · Critical Reviews in Oncology/Hematology
59. Potential role of immunotherapy in advanced non-small-cell lung cancer
    Ramon Andrade de Mello, Ana Flávia de Holanda Veloso, Paulo Esrom Moreira Catarina, Sara Nadine, Γεώργιος Αντωνίου · 2016 · OncoTargets and Therapy
60. Autoantibodies as Potential Biomarkers in Breast Cancer
    Jingyi Qiu, Bailey Keyser, Zuan‐Tao Lin, Tianfu Wu · 2018 · Biosensors
61. Evaluation of a Hybrid Capture–Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes
    Leonie I. Kroeze, Richarda M. de Voer, Eveline J. Kamping, Daniel T. von Rhein, Erik A. M. Jansen, Mandy J. W. Hermsen, Massimo C.P. Barberis, Johan Botling, Eva Maria Garrido-Martin, Florian Haller et al. · 2020 · Journal of Molecular Diagnostics
62. Vascular endothelial growth factor and programmed death‐1 pathway inhibitors in renal cell carcinoma
    Charlene M. Mantia, David F. McDermott · 2019 · Cancer
63. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma
    Gang Ji, Qi Yang, Song Wang, Xiaolong Yan, Qiuxiang Ou, Li Gong, Jinbo Zhao, Yongan Zhou, Feng Tian, Jie Lei et al. · 2024 · Genome Medicine
64. PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma
    Jan Budczies, Gunhild Mechtersheimer, Carsten Denkert, Frederick Klauschen, Sadaf Shabbir Mughal, Priya Chudasama, Michael Ludwig Bockmayr, Korinna Jöhrens, Volker Endris, Amelie Lier et al. · 2017 · OncoImmunology
65. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non–Small-Cell Lung Cancer Patients
    Kazuki Takada, Gouji Toyokawa, Tatsuro Okamoto, Mototsugu Shimokawa, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura et al. · 2017 · Clinical Lung Cancer
66. Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study
    Anne-Marie Boothman, Marietta Louise Juanita Scott, M. Ratcliffe, Jessica L. Whiteley, Phillip A. Dennis, Catherine Wadsworth, Alan D. Sharpe, Naiyer A. Rizvi, Marina Chiara Garassino, Jill Walker · 2019 · Journal of Thoracic Oncology
67. Computational Insight Into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship
    Danfeng Shi, Xiaoli An, Qifeng Bai, Zhitong Bing, Shuangyan Zhou, Huanxiang Liu, Xiaojun Yao · 2019 · Frontiers in Chemistry
68. Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
    Raghav Sundar, Elizabeth Catherine Smyth, Siyu Peng, Joe Poh-Sheng Yeong, Patrick B. O. Tan · 2020 · Frontiers in Oncology
69. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma
    Ilaria Girolami, Liron Pantanowitz, Özgür Mete, Matteo Brunelli, Stefano Marletta, Chiara Colato, Pierpaolo Trimboli, Anna Crescenzi, Massimo Bongiovanni, Mattia Barbareschi et al. · 2020 · Endocrine Pathology
70. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer
    Maxim Sorokin, Elena V Poddubskaya, Madina P. Baranova, Alex Glusker, Lali M. Kogoniya, Маркарова Екатерина Васильевна, Daria O. Allina, Maria Suntsova, Victor Tkachev, Andrew Garazha et al. · 2020 · Molecular Case Studies
71. LncRNA NUTM2A‐AS1 positively modulates TET1 and HIF‐1A to enhance gastric cancer tumorigenesis and drug resistance by sponging miR‐376a
    Wang, Ji, Yu, Ziyang, Wang, Jun, Shen, Yidan, Qiu, Junlan, Zhuang, Zhixiang · 2020 · Cancer Medicine
72. PD-L1 Status in Refractory Lymphomas
    Semir Vranić, Nilanjan Ghosh, Jeffery Kimbrough, Nurija Bilalović, Ryan Bender, David Arguello, Yvonne Veloso, Aida Dizdarević, Zoran Gatalica · 2016 · PLoS ONE
73. Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology
    Thomas Hecking, Thore Thiesler, Cynthia Schiller, J. Lunkenheimer, Tiyasha Hosne Ayub, Andrea Rohr, Mateja Condic, Mignon-Denise Keyver-Paik, Rolf Fimmers, Jutta Kirfel et al. · 2017 · Oncotarget
74. T cell exhaustion in cancer: Mechanisms and clinical implications
    Jincheng Wang, Yong Xu, Zheng‐Ming Huang, Xiaojie Lu · 2017 · Journal of Cellular Biochemistry
75. Circular RNA CHST15 Sponges miR-155-5p and miR-194-5p to Promote the Immune Escape of Lung Cancer Cells Mediated by PD-L1
    Jianru Yang, Yang Jia, Bing Wang, Shengrong Yang, Kun Du, Yujie Luo, Yunhe Li, Bing Zhu · 2021 · Frontiers in Oncology
76. Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
    Roy, Dia, Gilmour, Cassandra, Patnaik, Sachin, Wang, Li Lily · 2023 · Frontiers in Immunology
77. Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells
    Chen, Mingshui, Sharma, Aditi, Lin, Yanling, Wu, Yanheng, He, Qi, Gu, Yushu, Xu, Zhi Ping, Monteiro, Michael, Gu, Wenyi · 2019 · BMC Cancer
78. Immune checkpoint inhibitors for the treatment of melanoma
    Francesco Sabbatino, Luigi Liguori, Stefano Pepe, Soldano Ferrone · 2022 · Expert Opinion on Biological Therapy
79. New insights into the function and pathophysiology of the ectodomain sheddase A Disintegrin And Metalloproteinase 10 (ADAM10)
    David Rosenbaum, Paul Säftig · 2023 · FEBS Journal
80. Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer
    Shigehiro Koganemaru, Naoko Inoshita, Yuji Miura, Yu Miyama, Yudai Fukui, Yukinori Ozaki, Kenji Tomizawa, Yutaka Hanaoka, Shigeo Toda, Koichi Suyama et al. · 2017 · Cancer Science
81. Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics
    Mina Nikanjam, Philip R. Cohen, Shumei Kato, Jason Keith Sicklick, Razelle Kurzrock · 2018 · Annals of Oncology
82. The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
    Christoph M. Griessinger, Tove Olafsen, Alessandro Mascioni, Ziyue Karen Jiang, Charles Zamilpa, Fang Jia, Michael Y. Torgov, Jason M. Romero, Filippo Marchioni, Daulet Satpayev et al. · 2020 · Cancer Research
83. Challenges and Opportunities in the Statistical Analysis of Multiplex Immunofluorescence Data
    Christopher M. Wilson, Oscar E. Ospina, Mary K. Townsend, Jonathan V. Nguyen, Carlos Moran Segura, Joellen M. Schildkraut, Shelley S. Tworoger, Lauren Cole Peres, Brooke L. Fridley · 2021 · Cancers
84. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
    Yuanfang Xin, Guoshuang Shen, Yonghui Zheng, Yumei Guan, Xingfa Huo, Jinming Li, Dengfeng Ren, Fuxing Zhao, Zhen Liu, Zitao Li et al. · 2021 · BMC Cancer
85. TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
    Surui Liu, Jin Seok Yu, Hui Zhang, Jie Liu · 2022 · Frontiers in Oncology
86. Current Status in Rechallenge of Immunotherapy
    Han Hwa Hu, Ke Wang, Rong Jia, Zixun Zeng, Min Zhu, Yuanle Deng, Zhujuan Xiong, Jianning Tang, Hua Xie, Yi Wang et al. · 2023 · International Journal of Biological Sciences
87. Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma
    Mikko Siurala, Riikka Havunen, Dipongkor Saha, Dave Lumén, Anu J. Airaksinen, Siri Tähtinen, Víctor Cervera-Carrascón, Simona Bramante, Suvi Parviainen, Markus J. V. Vähä-Koskela et al. · 2016 · Molecular Therapy
88. PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
    Jinfeng Cao, Niels J. Brouwer, Kate Richards, Marina Marinkovic, Sjoerd G. van Duinen, Daan P. Hurkmans, Els M.E. Verdegaal, Ekaterina S. Jordanova, Martine Johanna Jager · 2017 · Oncotarget
89. Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression
    Arutselvan Natarajan, Chirag B. Patel, Frezghi G. Habte, Sanjiv Sam Gambhir · 2018 · Scientific Reports
90. Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response
    Carolyn Shembrey, Nicholas D. Huntington, Frédéric Hollande · 2019 · Cancers
91. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
    Valérie Cristina, Ruth Gabriela Herrera Gómez, Petr Szturz, Vittoria Guro Espeli, Marco Siano · 2019 · International Journal of Molecular Sciences
92. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect
    Tian Gao, Zheng Mao, Wenjing Li, Renjun Pei · 2020 · Journal of Materials Chemistry B
93. Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients
    Min Deng, Shaohua Li, Xu Fu, Xiaopeng Yan, Jun Chen, Yudong Qiu, Rong Guo · 2021 · Cancer Cell International
94. CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy
    Sophia Magkouta, Photene C. Vaitsi, Apostolos Pappas, Marianthi P. Iliopoulou, Chrysavgi Kosti, Katherina Psarra, Ioannis Kalomenidis · 2021 · Cancers
95. Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
    Carine Ngo, Sophie C. Postel-Vinay · 2022 · Biomedicines
96. PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score
    Yoon Ah Cho, Hyunwoo Lee, Deok Geun Kim, Hyunjin Kim, Sang Yun Ha, Yoon‐La Choi, Kee‐Taek Jang, Kyoung‐Mee Kim · 2021 · Cancers
97. Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer
    Ivan Cohen, Ronald G. Blasberg · 2017 · Breast Cancer Basic and Clinical Research
98. PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study
    Hyojin Kim, Hyun Jung Kwon, Soo Young Park, Eunhyang Park, Jin-Haeng Chung · 2017 · Oncotarget
99. Epigenetic regulators of programmed death-ligand 1 expression in human cancers
    Sachin Kumar, Surender Kumar Sharawat · 2018 · Translational research
100. Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer
     Yueming Zhang, Anqi Lin, Yonghe Li, Weimin Ding, Hui Meng, Peng Luo, Jian Zhang · 2020 · Frontiers in Cell and Developmental Biology